Investors

Updates

  • Home
  • Investors
  • Updates
Investors
Updates
Daehan New Pharm Enters the Cell Culture Media Business for Biopharmaceutical Research and Production
2013.01.22

Dae Han New Pharm Co., Ltd. Enters the Cell Culture Media Business for Biopharmaceutical Research and Production

 

Supply of culture media used by Dr. Shinya Yamanaka, Nobel Laureate in Physiology or Medicine in 2012, to the domestic market

Targeting the domestic cell culture media market worth 300 billion KRW through factory construction promotion

Following the domestic supply of Protein A last November, establishing the foundation for the second phase of biopharmaceutical business growth

 

Mid-sized pharmaceutical company Dae Han New Pharm (CEO Bae Kun-Woo) announced that it has formed a strategic partnership with Japanese companies CSTI and Ragass for the domestic supply of cell culture media, essential for biopharmaceutical research, development, and production, and for building a domestic production plant.

 

Cell culture media refers to liquid or powder products containing various amino acids and growth factors for culturing animal-derived cells or tissues. With the active development of biopharmaceuticals, the domestic culture media consumption market is estimated to be worth approximately 300 billion KRW.

 

Conventional culture media uses serum for cultivation, which can trigger immune rejection reactions, but CSTI’s serum-free media only contain clinically proven safe ingredients, making them suitable for clinical use.

 

Through this partnership, Dae Han New Pharm can supply various culture media domestically, including:

 

Culture media for CHO cells used in therapeutic protein production

 

Culture media for NK cells, a type of white blood cell

 

Culture media for LAK cells which inhibit cancer growth

 

Culture media for iPS cells, induced pluripotent stem cells

 

Notably, CSTI’s iPS cell culture media is globally recognized for its technology and safety, supplied to Dr. Shinya Yamanaka, Nobel Laureate in Physiology or Medicine 2012. Its T-lymphocyte culture media occupies 70% of the Japanese immune cell therapy market.

 

CEO Bae Kun-Woo of Dae Han New Pharm stated, “We expect strong demand from biotech companies and university research facilities in the domestic market for culture media supply with competitive quality and pricing,” and “We will provide high-quality, customized one-on-one technical services.”

 

Meanwhile, Dae Han New Pharm signed a consulting agreement with Japanese company Ragass for culture media manufacturing and technology transfer for the construction of a domestic plant. With the introduction of global technology, they expect to enable direct domestic production and supply of culture media, improving technology and price competitiveness simultaneously.

 

Starting with the first phase of the bio-business with the Protein A supply contract with Korea, China, Japan, and the US in November last year, Dae Han New Pharm solidifies its growth foundation for the second phase with the supply and production contract for cell culture media.

 

Glossary:

CHO cells (Chinese Hamster Ovary cells)

These are cells derived from hamster ovaries mainly used in therapeutic protein production for biopharmaceutical development.

 

iPS cells (induced Pluripotent Stem cells)

Mature somatic cells genetically reprogrammed to return to a pluripotent stem cell state similar to embryonic stem cells, also known as "reprogrammed stem cells." Successful derivation of such cells from adult skin cells was independently achieved by Professor James Thomson’s team in the US and Professor Shinya Yamanaka’s team in Japan in late 2007.

 

LAK cells (lymphokine activated killer cells)

Cells derived by culturing human peripheral lymphocytes or mouse lymphocytes with lymphokines such as interleukin-2 (IL-2), which become activated and exhibit anti-tumor activity.

 

NK cells (natural killer cells)

A type of white blood cell produced in the human bone marrow that can directly kill cancer cells, known in Korean as “natural killer cells,” possessing specific proteins (MHC).

 

Serum

The transparent liquid separated when fresh blood is left standing, containing various growth factors and used as an additive in cell culture.

 

T-lymphocytes

Lymphocytes involved in immune response; T cells assist B cells in antibody production and directly destroy foreign substances. Abnormalities in T cells can lead to immunodeficiency and diseases such as adult T-cell leukemia.
List
Article 1 (Purpose)
These Terms and Conditions are intended to define the terms of use, rights, obligations, and responsibilities between Daehan Nupharm Co., Ltd. (hereinafter the “Company”) and users regarding all websites operated by the Company (hereinafter the “Site”) and any online contents provided through the Site (hereinafter the “Contents”).
Article 2 (Effect and Amendment of the Terms)
1. These Terms shall apply to all users (including job applicants) who wish to use the Site and its Contents, as stated at the bottom of the Site.
2. Users who access the Site or register by giving consent shall be deemed to have agreed to these Terms.
3. The Company may amend these Terms to the extent that such changes do not violate relevant laws including the Act on the Regulation of Terms and Conditions. Any amended Terms shall take effect upon notice through the Site.
4. Continued use of the Site or the Contents after such notice shall be deemed acceptance of the revised Terms.
Article 3 (Matters Not Specified in the Terms)
Any matters not specified herein shall be governed by relevant laws and regulations.
Article 4 (Obligations)
Obligations of the Company
The Site shall maintain the confidentiality of users’ personal information and use it solely for purposes within the Site, such as improving and operating services or providing new information. It shall not be transferred to any third party for any other purpose. (However, exceptions shall be made where disclosure is legally required—for example, upon a lawful request by investigative authorities or the Korea Communications Standards Commission.)

Obligations of Users and Job Applicants
1. Users must comply with these Terms, applicable laws, and all notices posted on the Site.
2. Users may not engage in profit-seeking activities using the information or Contents without prior consent from the Company. That is, information or Contents obtained from the Site may not be reproduced, modified, published, or broadcast without the Company’s prior approval.
3. Users must not alter or distribute information or Contents provided by the Site in any manner that violates public order or decency
4. Users must not infringe any intellectual property rights, including copyrights, without the Company’s consent, nor harm the reputation of the Site or third parties, or interfere with their business.
Article 5 (Service Availability)
The Site shall, in principle, be available year-round without interruption, except in cases of business or technical difficulties or other unavoidable circumstances. However, the Company may partially or fully restrict service when necessary—such as for maintenance, system failure, or service overload caused by force majeure.
Article 6 (Provision, Restriction, and Suspension of Information)
1. The administrator may, in the course of operating the Site, provide various information through channels other than the Site itself.
2. The Company may restrict or suspend service when it becomes impossible to continue providing it.
Article 7 (Disclaimer)
1. The Company shall not be liable for any failure to operate the Site or provide Contents due to policy changes, special circumstances, or force majeure.
2. The Company shall not be liable for any service interruptions or restrictions arising from causes attributable to the user.
3. The Company shall not be responsible for information posted by users; all responsibility lies with the user.
4. The Company shall not be liable for any disputes or issues between users and third parties arising through the Site.
5. The Company shall not be liable for any damages caused by the intentional acts or negligence of users or visitors arising from the Site or its Contents.
6. The Company shall not be responsible for users’ failure to gain expected benefits from the service, or for any damages resulting from their choice or use of service materials.
Article 8 (Compensation for Damages)
The Company shall not be liable for any damages incurred by users in connection with the use of the Site or its Contents.
Article 9 (Governing Law and Jurisdiction)
Any disputes or lawsuits arising between the Company and users in relation to the use of the Site and its Contents shall be subject to the jurisdiction of the court having authority over the location of the Company’s head office, and the governing law shall be the laws of the Republic of Korea.
Daehan Nupharm Co., Ltd. (hereinafter referred to as the “Company”) values customers’ personal information and complies with the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc.
Through this Privacy Policy, the Company informs you of how and for what purposes your personal information is used,
and what measures are being taken to protect your personal data.
In the event of any amendments to this Privacy Policy, the Company will notify users through website announcements (hereinafter referred to as the “Site”) or individual notices.
This policy has been effective since January 1, 2014.
Items of Personal Information Collected
The Company collects the following personal information for purposes such as job applications, consultations, inquiries, and service requests.

Collected items: name, date of birth, gender, phone number (mobile/landline), address, email, photo, educational background, occupation, career details, company name, department, position, period of employment, educational history, career history, salary, job description, projects undertaken, detailed work tasks, major achievements, reason for resignation, qualifications, family information, self-introduction, veteran status, disability status, and any personal information submitted by the user for recruitment purposes. Additionally, during service use or business processing, the following information may be automatically generated and collected:
Type of browser and operating system, visit records (IP address, access time), and cookies.
Method of collection: through the Site (general inquiries, product inquiries, partnership proposals, recruitment).
Purpose of Collecting and Using Personal Information
The Company utilizes the collected personal information for the following purposes:
Responding to various inquiries.
User management and handling of complaints or civil petitions.
Evaluation and processing of recruitment applications.
Retention and Use Period of Personal Information
In principle, personal information is destroyed without delay once the purpose of collection and use has been fulfilled.
However, if retention is required under relevant laws and regulations, the Company may retain user information for a specific period as prescribed by such laws.
Items retained: Personal information items specified above.
Legal basis for retention: Consumer protection and data management.
Retention period: 3 years.
Records related to consumer complaints or dispute resolution: 3 years (in accordance with the Act on the Consumer Protection in Electronic Commerce, etc.)
Procedures and Methods of Personal Information Destruction
In principle, the Company promptly destroys personal information once the purpose of collection and use has been achieved. The procedures and methods of destruction are as follows:
Destruction procedures: Information entered by users for purposes such as membership or application submission is transferred to a separate database (or stored separately in paper form) after the purpose has been achieved. It is retained for a certain period in accordance with internal policies and relevant laws (refer to retention and use period), and then destroyed. Personal information transferred to a separate database is not used for any purpose other than as required by law.
Destruction method: The data is deleted using a database deletion method.
Provision of Personal Information
The Company does not, in principle,
When users have given prior consent.
When required by law or when an investigative agency requests such information in accordance with legally prescribed procedures.
Entrustment of Collected Personal Information
The Company does not entrust users’ personal information to external companies without prior consent.
Should such entrustment become necessary in the future, the Company will notify users of the entrusted party and the scope of the entrusted tasks, and obtain prior consent when required.
Rights of Users and Legal Representatives, and Exercise Thereof
Users may, at any time, view or modify their registered personal information and may also request withdrawal of membership.
If you contact the Personal Information Manager in writing, by phone, or via e-mail, the Company will take prompt action.
When you request correction of an error in your personal information, the Company will not use or provide such information until the correction has been completed.
If incorrect information has already been provided to a third party, the Company will notify the third party of the correction without delay so that it may be applied.
Personal information that has been canceled or deleted at the user’s request is handled according to the “Retention and Use Period of Personal Information” policy and will not be viewed or used for any other purpose.
For users under the age of 14, their legal representative has the right to access or correct the child’s personal information and to withdraw consent to its collection and use.
Use of Cookies
Purpose of Using Cookies
Cookies are used to prevent duplicate display of pop-up notifications.
Installation, Operation, and Rejection of Cookies
Users have the option to accept or reject the installation of cookies. Accordingly, users can set their web browser options to allow all cookies, to confirm each time a cookie is stored, or to reject all cookies.
By adjusting the settings of the web browser in use, users may allow all cookies, be prompted to confirm each time a cookie is saved, or refuse the storage of all cookies.
Example of setting method (for Internet Explorer): Tools at the top of the web browser → Internet Options → Privacy tab.
Personal Information Complaint and Inquiry Service
To protect customers’ personal information and handle related complaints, the Company designates the following department and Personal Information Manager
Customer Service Department: IT Team, Management Information Division
Personal Information Manager: Park Kangwon
Phone No.: +82-31-778-2626
Email: webmaster@dhnp.co.kr

You may contact the Personal Information Manager or the responsible department regarding any inquiries or complaints related to personal information protection arising from the use of the Company’s services.
The Company will provide prompt and adequate responses to your inquiries.
For further reports or consultations concerning personal data infringement, please contact the following organizations:

1. Personal Information Infringement Report Center (www.1336.or.kr/ No area code 118)
2. Korea Internet & Security Agency, Privacy Mark Certification Committee (www.eprivacy.or.kr/+82-2-580-0533–4)
3. Supreme Prosecutors’ Office Cyber Crime Investigation Center (http://icic.sppo.go.kr/+82-2-3480-3600)
4. National Police Agency Cyber Terror Response Center (www.ctrc.go.kr/+82-2-392-0330)